ESMO – This novel combination therapy holds great promise for BRCA-mutated metastatic Breast Cancers

ESMO shared a post on LinkedIn:

“ESMOBreast24: phase 2 data on combining olaparib, durvalumab, and fulvestrant for ER+/HER2- metastatic Breast Cancer with germline BRCA1/2 or other DNA repair mutations.

Key Results:

At median follow-up of 24.6 months, 66% PFS rate at 24 weeks overall and 76% in gBRCA1/2m carriers

Overall, median PFS of 9.3 months, ORR 41%, median OS 30 months

Median PFS of 12.6 months in gBRCA1/2m carriers

The triplet showed a synergic effect, with higher benefits in BRCA1/2 carriers.

This novel combination of PARP inhibition, immunotherapy, and endocrine therapy holds great promise, especially for BRCA-mutated metastatic Breast Cancers. ”

Read further.
Source: ESMO/LinkedIn